Ref. No.P-66/2026-27/60
November 23rd, 2026

The Relationship Manager,
Department of Corporate Relations
BSE Limited,
P.J. Towers, Dalal Street
Fort, MUMBAI – 400 001

Dear Sir / Madam,

Sub: Intimation under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

This is to inform you that 3B BlackBio Dx Ltd. (hereinafter referred to as "**3B**") along with its subsidiary TRUPCR® Europe Limited (hereinafter referred to as "**TPE**") is pleased to announce that it has entered into a definitive agreement with Foresight Regional Investment LP (hereinafter referred to as "**Foresight**"), London UK, to acquire 100% shares of Epistem Limited (hereinafter referred to as "**Epistem**") for an upfront cash consideration of £723,000 (the"Acquisition") Cash free & Debt free basis with normalized working capital .

3B shall acquire 70% of the total paid-up share capital and TPE shall acquire 30% of the total paid-up share capital by 31st December 2026, and accordingly Epistem shall become a subsidiary of the company as per the conditions set out in the Share Purchase agreement signed between the parties.

The details required under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure I. A business update on the aforesaid acquisition is enclosed as Annexure II for your perusal and information.

Further, pursuant to Regulation 30 (8) of the SEBI LODR Regulations the enclosed disclosures and the business update are also made available on the company's website.

This is for your information and further dissemination.

Thanking You,
For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

NIKHILKUBER DUBEY

Digitally signed by NIKHILKUBER DUBEY
Date: 2026.11.23 22:57:36 +05'30'

Nikhil Kuber Dubey
WholeTime Director
DIN: 00538049

Encl: As above

Annexure-I

Disclosure under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

S.No.	Particulars	Details
a)	Name of the Target Entity, details in Brief such as Size, Turnover etc.;	Epistem Limited 48 Grafton Street, Manchester United Kingdom M13 9XX Last 2 years turnover: £2.49 Million (FY'24) £1.85 Million (FY'25)
b)	Whether the acquisition would fall within Related Party Transaction(s) and whether the Promoter/ Promoter Group/ Group Companies have any interest in the Entity being acquired? If Yes, nature of interest and details thereof and whether the same is done at "Arm's Length";	The acquisition does not fall within related party transactions. The promoter / promoter group have no interest in the entity being acquired.
c)	Industry to which the Entity being acquired belongs;	Biotechnology Research (Pre-Clinical & Early Clinical CRO)
d)	Objects and Impact of Acquisition (including but not limited to, Disclosure of Reasons for Acquisition of Target Entity, if its Business is outside the main line of Business of the listed entity);	1. Epistem is a Manchester based provider of preclinical and clinical research services for over several years, having expertise in genetic and protein biomarker testing, histology and NGS services, to pharmaceutical, biotechnology and academic clients. This acquisition will strengthen 3B's position in the global biotechnology and life sciences space. 2. Epistem is a leading provider of Next Generation Sequencing (NGS) services on difficult and very small samples, offering a wide range of sequencing options for DNA and RNA samples, built on decades of experience. 3B plans to leverage this experience to co-develop oncology assays utilizing advanced Next-Generation Sequencing (NGS) technology.
e)	Brief Details of any Governmental or Regulatory Approvals Required for the Acquisition;	None
f)	Indicative Time Period for Completion of the Acquisition;	Acquisition to be completed by 31st December, 2026
g)	Consideration - Whether Cash Consideration or Share Swap or any Other Form and Details of the same;	All Cash
h)	Cost of Acquisition and/or the Price at	Acquisition of the shares of Epistem Limited will

<table>
<tr><td></td><td>Which the Shares are Acquired;</td><td>be done at £723,000, Cash free & Debt free basis with normalized working capital.</td></tr>
<tr><td>i)</td><td>Percentage of Shareholding / Control Acquired and / or Number of Shares Acquired;</td><td>1. 70% Equity Shares will be acquired by 3B BlackBio Dx Limited from Foresight Regional Investment LP London UK.

2. 30% Equity Shares will be acquired by TRUPCR® Europe Limited (subsidiary of 3B BlackBio Dx Limited) Limited from Foresight Regional Investment LP , London UK.</td></tr>
<tr><td>j)</td><td>Brief Background about the Entity Acquired in terms of Products/Line of Business Acquired, Date of Incorporation, History of last 3 years turnover, Country in which the Acquired Entity has presence and any other Significant Information (in brief);</td><td>Epistem Limited, which is a private limited company under the laws of England and Wales. Incorporated in 2017, Epistem is a Manchester based contract research organization offering preclinical and clinical services, genetic and protein biomarker testing, histology and next-generation sequencing, to pharmaceutical, biotechnology and academic customers.

Details of Revenue:
<table>
<tr><th>Year</th><th>Approx. Revenue</th></tr>
<tr><td>FY2023</td><td>£2.16 Million</td></tr>
<tr><td>FY2024</td><td>£2.49 Million</td></tr>
<tr><td>FY2025</td><td>£1.85 Million</td></tr>
</table></td></tr>
</table>

Annexure –II

BUSINESS UPDATE: 3B BLACKBIO DX LIMITED AND TRUPCR EUROPE LIMITED JOINTLY ACQUIRES 100% STAKE IN EPISTEM LIMITED, MANCHESTER

November 23rd 2026, Bhopal, (M.P.) INDIA: 3B BlackBio Dx Ltd. **(3B)** along with its subsidiary TRUPCR® Europe Limited **(TPE)** is pleased to announce that it has entered into a definitive agreement with Foresight Regional Investment LP **(Foresight)**, London UK to acquire 100% shares of Epistem Limited, Manchester ("**Epistem**") for an upfront cash consideration of £723,000 (the "**Acquisition**") on a Cash free & Debt free basis with normalized working capital.

According to the latest audited financial results shared by **Epistem**, the company reported revenue of £1.85 Million for the financial year ended December 31, 2025 ("FY25"). The company achieved a strong gross margin of approximately 55.8%. However, driven by specialized operational overheads, **Epistem** recorded a negative adjusted EBITDA of £0.23 Million.

Current fiscal year driven by expanded commercial and marketing initiatives, Epistem is projected to reach £2.4 million in revenue, marking an inflection point into positive adjusted EBITDA. Looking ahead, the company is positioned to deliver sustainable, organic top-line growth of 10–15% annually alongside expanding EBITDA margins over the medium term horizon .

Epistem operates within the Global Pre-Clinical & Early Clinical CRO Market, which is estimated to be worth $6.5bn and is expected to grow by a CAGR of 7.5% to $10.5bn by 2032, as drug developers continue to seek the services of specialist suppliers. Epistem has pioneered techniques using plucked scalp hair and laser capture micro dissected material to provide gene expression biomarker information to drug development programs. Epistem serves a varied customer base of both large and small-mid-sized pharma companies, with a small number of academic institutions.

As Epistem is a leading provider of Next Generation Sequencing (NGS) services on difficult and very small samples, offering a wide range of sequencing options for DNA and RNA samples, built on decades of experience. 3B plans to leverage this experience to co-develop oncology assays utilizing advanced Next-Generation Sequencing (NGS) technology.

Epistem employs a dedicated team of 22 professionals across key functions including R&D, Sales, Marketing, and Administration. The company operates from a facility in the University of Manchester, United Kingdom, which houses its R&D and offices.

Since 3B specializes in the development and manufacturing of IVD products focused on oncology and infectious disease diagnostics, this acquisition is complementary, as Epistem's expertise in genetic and protein biomarker testing, histology and next-generation sequencing (NGS) services aligns closely with 3B's molecular diagnostics and NGS portfolio. With both Epistem and TPE based in Manchester, the two companies will work collaboratively to leverage their combined scientific capabilities, customer relationships and infrastructure, enhancing value for partners and customers worldwide.

Mr. Dhirendra Dubey (Founder CEO – 3B BlackBio Dx Limited) says, "We are delighted to welcome Epistem into the 3B BlackBio Group. The acquisition brings together highly complementary scientific and technical capabilities, creating exciting opportunities across research, biomarker development, molecular diagnostics and commercialization. "

About 3B BlackBio Dx Limited:

3B is a research-driven company dedicated to the development, validation, and manufacturing of high-quality *in vitro* diagnostic (IVD) products. Under its brands—TRUPCR®, TRURAPID®, and TRUNGS®—**3B** offers a comprehensive portfolio focused on oncology and infectious disease diagnostics.

With over 14 years of industry expertise and more than 100 successfully launched products, 3B is committed to advancing patient care through innovative and reliable diagnostic solutions. All molecular diagnostic kits are developed and manufactured in compliance with the highest quality standards, backed by ISO 13485:2016 certification through BSI, UK.

3B's subsidiary, **TPE**, based in Manchester, UK, serves as the company's European headquarters. Also ISO 13485 certified through BSI UK, TPE oversees the manufacturing, sales, and marketing of IVD products kits across Europe, Latin America, and Africa, further strengthening 3B's global footprint.

About Epistem Limited:

Incorporated in 2017 and headquartered in Manchester, United Kingdom, Epistem is a contract research organization providing preclinical and clinical research services, including biomarker discovery, genetic and protein biomarker testing, histology and next-generation sequencing (NGS), to pharmaceutical, biotechnology and academic clients.

Epistem operates from a facility at the University of Manchester, which houses its R&D and offices, and employs a team of 22 professionals. Over more than several years, the company has built an established customer base of over 200 pharmaceutical and biotechnology companies.